KTKatarzyna Trojanowicz

Katarzyna Trojanowicz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katarzyna Trojanowicz has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Sylwia Szczepara

    Department of Cardiac and Vascular Diseases, St. John Paul II Hospital, Kraków, Poland; Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Institute of Cardiology, St. John Paul II Hospital, Kraków, Poland

    2 shared publications
  • Grzegorz Kopeć

    Department of Cardiac and Vascular Diseases, St. John Paul II Hospital in Krakow, 31-202 Krakow, Poland

    1 shared publication
  • Joanna Natorska

    Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow Specialist Hospital Named After St. John Paul II, ul. Prądnicka 80, 31-202 Krakow, Poland

    1 shared publication
  • Katarzyna Holcman

    Department of Cardiac and Vascular Diseases, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland

    1 shared publication
  • Klaudia Bielecka

    Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland

    1 shared publication
  • Klaudia Pacia

    Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland

    1 shared publication

Latest Publications

  • Open Access

    A Coupled Inflammatory–Fibrotic–Nitrosative Axis in Patients with Patent Foramen Ovale and Cryptogenic Stroke

    by Michał Tworek, Katarzyna Trojanowicz, Zuzanna Sachajko, Monika Kowalik-Pandyra, Klaudia Pacia, Klaudia Bielecka, Sylwia Szczepara, Miłosz Tworek, Joanna Natorska, Grzegorz Kopeć, et al.

    Background: Patent foramen ovale (PFO) is associated with cryptogenic stroke, but mechanisms beyond paradoxical embolism remain unclear. Inflammation, fibrosis-related remodeling, and nitrosative stress may contribute to vascular vulnerability in these patients. The aim of this study was to evaluate inflammatory, fibrotic, and nitrosative biomarker profiles in patients with PFO and prior cryptogenic stroke and to determine whether these patients exhibit coupled inflammatory fibrotic nitrosative activation. Methods: This prospective, observational, single-center study included 92 patients aged p = 0.015), IL-18 (268.0 vs. 121.0 pg/mL; p < 0.001), and 3-NT (48.5 vs. 41.8 ng/mL; p = 0.046). Significant correlations were observed between IL-18 and galectin-3 (r = 0.565), IL-18 and 3-NT (r = 0.425), and galectin-3 and 3-NT (r = 0.292) (all p ≤ 0.002). Conclusions: Patients with PFO and prior cryptogenic stroke exhibit a distinct biomarker profile consistent with coupled inflammatory–fibrotic–nitrosative activation, suggesting a potential non-mechanical component of stroke susceptibility.

  • Open Access

    Looking for Fabry, Finding More: LVH Screening Yields Unexpected Gaucher Diagnosis

    by Sylwia Szczepara, Klaudia Pacia, Katarzyna Trojanowicz, Klaudia Bielecka, Michał Tworek, Zuzanna Sachajko, Katarzyna Holcman, Piotr Podolec, Monika Komar

    Objective: Fabry disease (FD) is a rare, X-linked lysosomal storage disorder resulting from deficient α-galactosidase A activity, which can manifest as left ventricular hypertrophy (LVH). We aimed to assess the prevalence of FD in an unselected cohort of patients with unexplained LVH. Methods and results: We screened 202 unrelated adults with LVH using enzymatic assays for α-galactosidase A in dried blood spots. Patients with low activity underwent GLA gene sequencing. Echocardiographic parameters were evaluated according to ESC guidelines. FD was diagnosed in 4 women (2%), each carrying distinct pathogenic GLA mutations. All affected individuals showed normal or borderline enzyme activity. Cardiac, renal, or neurological symptoms were observed variably among patients. Echocardiographic findings revealed slightly lower wall thickness and preserved systolic function in FD patients compared to those without FD. Cascade genetic screening identified 16 additional family members with the same mutations. One patient (0.5%) was incidentally diagnosed with Gaucher disease based on syndromic features and enzymatic testing. Conclusions: FD was identified in 2% of patients with unexplained LVH, who were females. Enzyme-based screening followed by targeted genetic testing is a cost-effective strategy for FD detection. Early diagnosis is essential for prompt treatment and family counselling, underscoring the importance of routine FD screening in patients with LVH of unclear aetiology. Our findings support the use of targeted screening for Fabry disease in patients with LVH and systemic features, and highlight the potential to identify other lysosomal disorders in selected cases.